Publication:
A New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues.

dc.contributor.authorRibeiro, Marcelo C
dc.contributor.authorRivera-Arbeláez, José M
dc.contributor.authorCofiño-Fabres, Carla
dc.contributor.authorSchwach, Verena
dc.contributor.authorSlaats, Rolf H
dc.contributor.authorTen Den, Simone A
dc.contributor.authorVermeul, Kim
dc.contributor.authorvan den Berg, Albert
dc.contributor.authorPérez-Pomares, José M
dc.contributor.authorSegerink, Loes I
dc.contributor.authorGuadix, Juan A
dc.contributor.authorPassier, Robert
dc.date.accessioned2024-02-27T14:58:05Z
dc.date.available2024-02-27T14:58:05Z
dc.date.issued2022-02-04
dc.description.abstractCardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) hold a great potential as human in vitro models for studying heart disease and for drug safety screening. Nevertheless, their associated immaturity relative to the adult myocardium limits their utility in cardiac research. In this study, we describe the development of a platform for generating three-dimensional engineered heart tissues (EHTs) from hPSC-CMs for the measurement of force while under mechanical and electrical stimulation. The modular and versatile EHT platform presented here allows for the formation of three tissues per well in a 12-well plate format, resulting in 36 tissues per plate. We compared the functional performance of EHTs and their histology in three different media and demonstrated that tissues cultured and maintained in maturation medium, containing triiodothyronine (T3), dexamethasone, and insulin-like growth factor-1 (TDI), resulted in a higher force of contraction, sarcomeric organization and alignment, and a higher and lower inotropic response to isoproterenol and nifedipine, respectively. Moreover, in this study, we highlight the importance of integrating a serum-free maturation medium in the EHT platform, making it a suitable tool for cardiovascular research, disease modeling, and preclinical drug testing.
dc.format.number2es_ES
dc.format.volume12es_ES
dc.identifier.doi10.3390/jpm12020214
dc.identifier.issn2075-4426
dc.identifier.journalJournal of personalized medicinees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/21372
dc.identifier.pubmedID35207702es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18597
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectcardiac performance
dc.subjectcontractile force
dc.subjectengineered heart tissues
dc.subjecthPSC-CMs
dc.subjectserum-free
dc.subjectversatile platform
dc.titleA New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files